Startup · $10.7m raised · Biotech and pharma
Every investor coverage indicates participated in a round BiomeBank raised.
| Investor | Rounds | Invested |
|---|---|---|
| Ellerston Capital | Unnamed stage | - |
| South Australian Venture Capital Fund | Unnamed stage | - |
| The Hospital Research Foundation | Unnamed stage | - |
Investors whose own portfolio pages list BiomeBank, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Artesian VC | its portfolio page ↗ |
| Artesian VC | its portfolio page ↗ |
Companies BiomeBank acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Chris Hall | Chair | Forbes Australia |
| Dr Sam Costello | Chief Executive Officer & Co-founder | Forbes Australia, BiomeBank team page |
| Dr Rob Bryant | VP Clinical Translation and Co-founder | SmartCompany, BiomeBank team page |
Stories naming BiomeBank. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Techboard's monthly roundup catalogues December 2022 startup raises, led by Synchron's $110m Series C, with health and biotech taking the largest share and 55 funding events captured totalling $546m.
Weekly roundup covering 14 startup raises totalling over $260 million, headlined by Synchron's $110 million round, plus Roller's shareholder liquidity payout, Partly's record New Zealand Series A, and several government grants.
Also Startup Daily·Startup Daily·Techboard·SmartCompany·SmartCompany·Startup Daily·SmartCompany·Startup News (WA)·Startup News (WA)
Biotech firm BiomeBank raised $10.65 million from Ellerston Capital, the South Australian Venture Capital Fund and The Hospital Research Foundation to expand manufacturing and advance its microbiome therapies.
Also SmartCompany·Techboard